HHS Price Negotiations For Part D Not A Problem For Medco, CEO Snow Says
Executive Summary
Medco is not worried about the possibility that the federal government may step in to negotiate drug prices for the Medicare Part D program, according to CEO David Snow
You may also be interested in...
Medco’s Health Reform Formula: Efficiencies Outweigh Access, Payment
Medco is promoting a health care reform agenda that emphasizes cost savings from more efficient and effective care instead of focusing on who pays the bills
Senate Blocks Medicare Drug Price Negotiation Bill From Floor Vote
Sen. Baucus’ effort to simply strike the non-interference clause, rather than requiring negotiations, did not garner enough support to force a vote.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.